Moleculin Biotech, Inc.
(NASDAQ : MBRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.19%177.170.7%$1337.76m
MRKMerck & Co., Inc. -0.07%91.110.7%$1167.06m
PFEPfizer Inc. -1.70%51.540.9%$1094.78m
LLYEli Lilly & Co. -1.48%319.451.1%$1030.26m
BMYBristol-Myers Squibb Co. -1.49%75.861.0%$992.94m
ABBVAbbVie, Inc. -0.97%151.671.9%$949.40m
AZNAstraZeneca Plc -1.47%65.101.0%$435.00m
SGENSeagen Inc. 0.83%178.405.7%$318.50m
TPTXTurning Point Therapeutics, Inc. -0.12%75.160.0%$287.74m
GSKGSK Plc -0.59%43.280.2%$274.87m
NVSNovartis AG -1.33%83.410.2%$162.39m
HZNPHorizon Therapeutics Plc -0.21%79.595.4%$161.46m
MRTXMirati Therapeutics, Inc. 3.49%69.471.6%$151.82m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.27%145.320.0%$141.94m
ALNYAlnylam Pharmaceuticals, Inc. 0.96%147.258.1%$141.86m

Company Profile

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.